{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:32:42Z","timestamp":1793399562307,"version":"4.5.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.2169\/internalmedicine.4708-20","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T22:04:50Z","timestamp":1590444290000},"page":"2177-2181","source":"Crossref","is-referenced-by-count":6,"title":["A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3"],"prefix":"10.2169","volume":"59","author":[{"given":"Hiroyasu","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Neurology, Nagoya City East Medical Center, Japan"},{"name":"Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Diabetes & Endocrinology, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Tomonari","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Nagasaki Kawatana Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Akao","sequence":"additional","affiliation":[{"name":"Department of Diabetes & Endocrinology, Nagoya City East Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422, 2011.","DOI":"10.1002\/ana.22312"},{"key":"2","unstructured":"2. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14: 1023-1036, 2015."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Li M, Han J, Zhang Y, et al. Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis. Eur J Neurol 26: 1296-e84, 2019.","DOI":"10.1111\/ene.13979"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52: 139-145, 2014.","DOI":"10.1016\/j.jaut.2013.12.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ishikawa H, Taniguchi A, Ii Y, et al. Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma. Neuromuscul Disord 27: 914-917, 2017.","DOI":"10.1016\/j.nmd.2017.06.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tsivgoulis G, Dervenoulas G, Tzartos SJ, et al. Double-seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies. Muscle Nerve 49: 930-931, 2014.","DOI":"10.1002\/mus.24166"},{"key":"7","unstructured":"7. Bokoliya SC, Kumar VP, Nashi S, et al. Anti-AChR, MuSK, and LRP4 antibodies coexistence: a rare and distinct subtype of myasthenia gravis from Indian subcontinent. Clin Chim Acta 486: 34-35, 2018."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Neufeld M, Maclaren N, Blizzard R. Autoimmune polyglandular syndromes. Pediatr Ann 9: 154-162, 1980.","DOI":"10.3928\/0090-4481-19800401-07"},{"key":"9","unstructured":"9. Shimizu C, Chiba H, Koike C. Autoimmuno Polyglandular syndrome. Nihon Rinsho Suppl 3: 565-570, 2006 (in Japanese)."},{"key":"10","unstructured":"10. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol 263: 826-834, 2016."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. de Meel RH, Lipka AF, van Zwet EW, et al. Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol 282: 123-125, 2015.","DOI":"10.1016\/j.jneuroim.2015.03.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Drachman DB. Myasthenia gravis. N Engl J Med 330: 1797-1810, 1994.","DOI":"10.1056\/NEJM199406233302507"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jamio\u0142kowska M, Bossowski A. 15-year old girl with APS type IIIc, 12 months post-thymectomy remission of myasthenia. Pediatr Endocrinol Diabetes Metab. 23: 49-55, 2017.","DOI":"10.18544\/PEDM-23.01.0074"},{"key":"14","unstructured":"14. Nakajima S, Matsunaga M, Shibata M, et al. A case of autoimmune type 1 diabetes mellitus complicated by Myasthenia Gravis and Graves' Disease. J Japan Diab Soc 58: 198-204, 2015 (in Japanese, Abstract in English)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. De Marchi SU, Cecchin E, De Marchi S. Autoimmune spontaneous chronic urticaria and generalized myasthenia gravis in a patient with polyglandular autoimmune syndrome type 3. Muscle Nerve 52: 440-444, 2015.","DOI":"10.1002\/mus.24635"},{"key":"16","unstructured":"16. Innico G, Frassetti N, Coppola B, Mariotti A, Lai S. Autoimmune polyglandular syndrome in a woman of 51 years. Eur Rev Med Pharmacol Sci 18: 1717-1719, 2014."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Duman O, Koken R, Baran RT, Haspolat S, Topaloglu H. Infantile anti-MuSK positive myasthenia gravis in a patient with autoimmune polyendocrinopathy type 3. Eur J Paediatr Neurol 18: 526-528, 2014.","DOI":"10.1016\/j.ejpn.2014.02.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Konno S, Ichijo T, Murata M, et al. Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis. Neurologist 15: 361-363, 2009.","DOI":"10.1097\/NRL.0b013e3181945437"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Briscoe NK, Mezei MM. Polyglandular autoimmune syndrome type 3 in a patient with ocular myasthenia gravis. Muscle Nerve. 40: 1064-1065, 2009.","DOI":"10.1002\/mus.21466"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 52: 2513-2521, 2009.","DOI":"10.1007\/s00125-009-1539-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsuki K, Juji T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86: 392-399, 1990.","DOI":"10.1172\/JCI114724"},{"key":"22","unstructured":"22. Knight CL, Cooray SD, Kulkarni J, Borschmann M, Kotowicz M. Thyroidectomy for the treatment of Graves' thyrotoxicosis in thioamide-induced agranulocytosis and sepsis. Endocrinol Diabetes Metab Case Rep. Forthcomig."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA. Thymectomy in nonthymoma early-onset myasthenia gravis in correlation with disease severity and muscle autoantibodies. Eur Neurol 49: 210-217, 2003.","DOI":"10.1159\/000070185"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/17\/59_4708-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T03:35:50Z","timestamp":1599276950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/17\/59_4708-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4708-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}